2,4,6-trichloro-1,3,5-triazine

Acute Toxicity: oral

Administrative data

Endpoint:

acute toxicity: oral

Type of information:

experimental study

Adequacy of study:

supporting study

Reliability:

4 (not assignable)

Rationale for reliability incl. deficiencies:

other: No GLP compliance

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

1993

Report date:

1988

Materials and methods

Test guideline

Test guideline 1

Qualifier:

according to guideline

Guideline:

OECD Guideline 401 (Acute Oral Toxicity)

Test guideline 2

Qualifier:

according to guideline

Guideline:

other: 84/449/EEC.

GLP compliance:

no

Test type:

acute toxic class method

Test material

Test material information

Constituent 1

Reference substance name:

2,4,6-trichloro-1,3,5-triazine

EC Number:

203-614-9

EC Name:

2,4,6-trichloro-1,3,5-triazine

Cas Number:

108-77-0

Molecular formula:

C3Cl3N3

IUPAC Name:

2,4,6-trichloro-1,3,5-triazine

Details on test material:

Cyanuric chloride, purity >95%.

Test animals

Species:

rat

Strain:

Wistar

Sex:

male/female

Details on test animals or test system and environmental conditions:

age males 6-10 weeks and females 8-10 weeks
weight males 215-400 g and females 190-250 g

Administration / exposure

Route of administration:

oral: gavage

Vehicle:

polyethylene glycol

Details on oral exposure:

food and water ad libitum (food was withheld 16 h prior to dosing).

Doses:

Single oral (gavage) administration at 240, 300, 325, 375 and 470 mg/kg bw

No. of animals per sex per dose:

5/sex/treatment

Control animals:

not specified

Statistics:

Probit analysis.

Results and discussion

Effect levels

Effect levels 1

Sex:

male

Dose descriptor:

LD50

Effect level:

315 mg/kg bw

Effect levels 2

Sex:

female

Dose descriptor:

LD50

Effect level:

327 mg/kg bw

Mortality:

Dose [mg/kg bw] \ effect Day 240 300 325 375 470
Sex M F M F M F M F M F
Mortality(A) 0-14 0/5 0/5 0/5 0/5 4/5 5/5 5/5 2/5 5/5 5/5
(A) Deaths occurred within 30 minutes to 3 hours post dosing.

Clinical signs:

Dose [mg/kg bw] \ effect Day 240 300 325 375 470
Sex M F M F M F M F M F
Clinical signs(B) 0-14 + + + + + + + +
(B) Consisted of: hypokinesia, somnolency, decreased muscle tone, loss of righting reflex, loss of pain reflex, loss of corneal reflex, piloerection, accelerated respiration and decreased body temperature.

Body weight:

Dose [mg/kg bw] \ effect Day 240 300 325 375 470
Sex M F M F M F M F M F
Body weight gain 0-14 d N/A N/A -- N/A N/A

Gross pathology:

Dose [mg/kg bw] \ effect Day 240 300 325 375 470
Sex M F M F M F M F M F
Necropsy(C) 0-14 + + + + + + + + + +
Histopathology(D) 0-14 + + + + + + +
(C) Macroscopic findings noted at necropsy included: stomach lesions such as reddening, inflation,
reddened gastric mucous membrane, thickened fundus, fusion with peritoneum/liver/spleen and reddening
of the intestinal mucosa.
(D) In animals found dead: diffuse necrosis, purulent exudate and ulceration (female high dose only) in the
forestomach and glandular stomach, peritonitis and congestion and/or vacuolisation of the liver. In
survivors (day 14): focal acanthosis and hyperkeratosis, subchronic submucosal inflamatory tissue and
subacute/subchronic ulceration in the forestomach and subchronic submucosal inflamatory tissue in the
glandular stomach.

Applicant's summary and conclusion

Conclusions:

Oral LD50 315 mg/kg (males) and 327 mg/kg (females).

Executive summary:

The acute toxicity after single oral administration of Cyanuric chloride was tested in rats (Wistar). The number of animals was 5/sex/treatment. The dosage single oral (gavage) administration was at 240, 300, 325, 375 and 470 mg/kg bw; food and water ad libitum (food was withheld 16 h prior to dosing). Mortality, clinical signs, body weight gain, necropsy and hystopathology were observed. Results for Oral LD50 were 315 mg/kg (males) and 327 mg/kg (females).